MX2020009487A - Sistemas y metodos para el tratamiento de hemoglobinopatias. - Google Patents

Sistemas y metodos para el tratamiento de hemoglobinopatias.

Info

Publication number
MX2020009487A
MX2020009487A MX2020009487A MX2020009487A MX2020009487A MX 2020009487 A MX2020009487 A MX 2020009487A MX 2020009487 A MX2020009487 A MX 2020009487A MX 2020009487 A MX2020009487 A MX 2020009487A MX 2020009487 A MX2020009487 A MX 2020009487A
Authority
MX
Mexico
Prior art keywords
methods
systems
hemoglobinopathies
treatment
portions
Prior art date
Application number
MX2020009487A
Other languages
English (en)
Inventor
Jennifer Leah Gori
De Lamothe-Dreuzy Edouard Aupepin
Jack Heath
John Anthony Zuris
Kaihsin Chang
Original Assignee
Editas Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Editas Medicine Inc filed Critical Editas Medicine Inc
Publication of MX2020009487A publication Critical patent/MX2020009487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan sistemas de edición genómica, ARN guía y métodos mediados por CRISPR para alterar porciones de los locus de HBG1 y HBG2, porciones del potenciador específico de eritroides del gen BCL11A, o una combinación de los mismos, en las células, y para aumentar la expresión de hemoglobina fetal.
MX2020009487A 2018-03-14 2019-03-14 Sistemas y metodos para el tratamiento de hemoglobinopatias. MX2020009487A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862643168P 2018-03-14 2018-03-14
US201862767488P 2018-11-14 2018-11-14
US201862773073P 2018-11-29 2018-11-29
PCT/US2019/022374 WO2019178426A1 (en) 2018-03-14 2019-03-14 Systems and methods for the treatment of hemoglobinopathies

Publications (1)

Publication Number Publication Date
MX2020009487A true MX2020009487A (es) 2020-12-10

Family

ID=65952168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009487A MX2020009487A (es) 2018-03-14 2019-03-14 Sistemas y metodos para el tratamiento de hemoglobinopatias.

Country Status (12)

Country Link
US (1) US20210254061A1 (es)
EP (1) EP3765614A1 (es)
JP (1) JP2021518102A (es)
KR (1) KR20200132924A (es)
CN (1) CN112020558A (es)
AU (1) AU2019236209A1 (es)
BR (1) BR112020018364A2 (es)
CA (1) CA3093702A1 (es)
IL (1) IL277234A (es)
MX (1) MX2020009487A (es)
SG (1) SG11202008956XA (es)
WO (1) WO2019178426A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242525B2 (en) 2014-03-26 2022-02-08 Editas Medicine, Inc. CRISPR/CAS-related methods and compositions for treating sickle cell disease
EA201891532A1 (ru) * 2015-12-28 2019-01-31 Новартис Аг Композиции и способы лечения гемоглобинопатий
EP3596217A1 (en) 2017-03-14 2020-01-22 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2018209158A2 (en) 2017-05-10 2018-11-15 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
WO2018220210A1 (en) * 2017-06-02 2018-12-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant lentiviral vector for stem cell-based gene therapy of sickle cell disorder
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2020033774A1 (en) * 2018-08-08 2020-02-13 Integrated Dna Technologies, Inc. Novel mutations that enhance the dna cleavage activity of acidaminococcus sp. cpf1
WO2020113112A1 (en) * 2018-11-29 2020-06-04 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
AU2020399638A1 (en) * 2019-12-08 2022-06-16 Editas Medicine, Inc. Modified cells and methods for the treatment of hemoglobinopathies
CA3170326A1 (en) * 2020-02-13 2021-08-19 Beam Therapeutics Inc. Compositions and methods for engraftment of base edited cells
US20230279438A1 (en) * 2020-05-13 2023-09-07 Inserm (Institut National De La Santé Et La Recherche Médicale) Base editing approaches for the treatment of betahemoglobinopathies
IL304969A (en) * 2021-02-11 2023-10-01 Koninklijke Nederlandse Akademie Van Wetenschappen Cure disease by transcriptional regulatory gene editing
EP4047095A1 (en) * 2021-02-22 2022-08-24 Eberhard Karls Universität Tübingen Medizinische Fakultät Method and composition for a targeted gene knockout
KR20240043772A (ko) * 2021-08-02 2024-04-03 에디타스 메디신, 인코포레이티드 헤모글로빈병증의 치료를 위한 시스템 및 방법
CN115851706A (zh) * 2021-09-24 2023-03-28 华东师范大学 一种碱基编辑系统及其应用
KR20230132341A (ko) 2022-03-07 2023-09-15 광주과학기술원 신속 DNA 진단을 위한 Cpf1 변이 단백질

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3066201T (pt) 2013-11-07 2018-06-04 Massachusetts Inst Technology Métodos e composições relacionadas com crispr com arng reguladores
ES2745769T3 (es) 2014-03-10 2020-03-03 Editas Medicine Inc Procedimientos y composiciones relacionados con CRISPR/CAS para tratar la amaurosis congénita de Leber 10 (LCA10)
WO2015148860A1 (en) 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating beta-thalassemia
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
AU2015355546B2 (en) * 2014-12-03 2021-10-14 Agilent Technologies, Inc. Guide RNA with chemical modifications
EP3230452A1 (en) * 2014-12-12 2017-10-18 The Broad Institute Inc. Dead guides for crispr transcription factors
EP3294896A1 (en) 2015-05-11 2018-03-21 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US20180273609A1 (en) * 2015-11-04 2018-09-27 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2017106657A1 (en) * 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
SG11201807859WA (en) * 2016-03-14 2018-10-30 Editas Medicine Inc Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
SG11201810179RA (en) 2016-04-19 2018-12-28 Broad Inst Inc Novel crispr enzymes and systems
WO2017191503A1 (en) * 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
EP3487523B1 (en) * 2016-07-19 2023-09-06 Duke University Therapeutic applications of cpf1-based genome editing
CA3077189A1 (en) * 2017-10-02 2019-04-11 Genedit Inc. Modified cpf1 guide rna
AU2018383712A1 (en) * 2017-12-11 2020-07-02 Editas Medicine, Inc. Cpf1-related methods and compositions for gene editing
US20190241911A1 (en) * 2018-02-06 2019-08-08 Ohio State Innovation Foundation Engineered guide rna and uses thereof

Also Published As

Publication number Publication date
WO2019178426A1 (en) 2019-09-19
JP2021518102A (ja) 2021-08-02
US20210254061A1 (en) 2021-08-19
CN112020558A (zh) 2020-12-01
EP3765614A1 (en) 2021-01-20
IL277234A (en) 2020-10-29
CA3093702A1 (en) 2019-09-19
AU2019236209A1 (en) 2020-10-01
KR20200132924A (ko) 2020-11-25
BR112020018364A2 (pt) 2020-12-29
SG11202008956XA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2020009487A (es) Sistemas y metodos para el tratamiento de hemoglobinopatias.
WO2018154462A3 (en) Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018209158A3 (en) CRISPR / RNA GUIDED NUCLEASE SYSTEMS AND METHODS
JP2019508051A5 (es)
AU2019271886A1 (en) Cas9-nucleic acid complexes and uses related thereto
MX2018008733A (es) Metodos para extender la capacidad replicativa de las celulas somaticas durante un proceso de cultivo ex vivo.
PH12021550849A1 (en) Compositions and methods for immunotherapy
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
EP4248979A3 (en) Pd-1 homing endonuclease variants, compositions, and methods of use
MX2021001971A (es) Metodos para fabricar paquetes mensajeros vegetales.
GB2573664A (en) Viral methods of T cell therapy
WO2016057835A3 (en) THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS
GB2578026A8 (en) Method for constructing GLRX1 gene knock-out animal model based on CRISPR/CAS9
MX2019015188A (es) Inserciones de adn no virales orientadas.
WO2016205688A3 (en) Rna-guided transcriptional regulation and methods of using the same for the treatment of back pain
MX2019014100A (es) Variantes de endonucleasas cblb, composiciones y metodos de uso.
AR101080A1 (es) Transformación de maíz haploide con una nucleasa específica de sitio
MX2020004541A (es) Edicion de genes de celulas primarias.
WO2016070037A8 (en) Massively parallel combinatorial genetics for crispr
BR112015023489A2 (pt) uso de rnas-guia truncads (tru - grnas) para aumentar a especificidade de edição de genoma com rna guiado
EP4286517A3 (en) Therapeutic uses of genome editing with crispr/cas systems
PH12017501218A1 (en) Rpe cell populations and methods of generating same
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
MX2019000850A (es) Plantas que comprenden genes restauradores para esterilidad citoplasmica masculina de tipo g en trigo, marcadores moleculares y sus usos.